Bone marrow (BM)-derived endothelial progenitor cells (EPCs), contribute to the angiogenesis dependent growth of tumors in mice and humans. EPCs regulate the angiogenic switch via paracrine secretion of proangiogenic growth factors, and by direct luminal incorporation into sprouting nascent vessels. MicroRNAs (miRNAs) have emerged as key regulators of several cellular processes including angiogenesis; however, whether miRNAs contribute to BM-mediated angiogenesis has remained unknown. Here, we show that genetic ablation of microRNA processing enzyme Dicer, specifically in the BM, decreased the number of circulating EPCs, resulting in angiogenesis suppression and impaired tumor growth. Furthermore, genome-wide deep sequencing of small RNAs revealed tumor EPC-intrinsic miRNAs including miR-10b and miR-196b; which have been previously identified as key regulators of HOX signaling and adult stem cell differentiation. Notably, we found that both miR-10b and miR-196b, are responsive to vascular endothelial growth factor (VEGF) stimulation, and show elevated expression in human high-grade breast tumor vasculature. Strikingly, targeting miR-10b and miR-196b led to significant defects in angiogenesis-mediated tumor growth in mice. Targeting these miRNAs may constitute a novel strategy for inhibiting tumor angiogenesis.
Introduction
For a solid tumor to grow and spread it must recruit blood vessels in a process referred to as the angiogenic switch (1) . Bone marrow (BM)-derived endothelial progenitor cells (EPCs) are important mediators of the angiogenic switch, through the production of paracrine factors, and by directly incorporating into the lumen of tumor neovasculature. Suppression of EPCs leads to a delayed angiogenic switch, which is associated with impaired tumor growth and spread (2) (3) (4) .
Tumor EPCs are phenotypically distinct from tumor vasculature, and other BM-derived cells (BMDCs) in the tumor microenvironment. Therefore, targeting EPC-intrinsic factors provides a therapeutic approach, likely to be devoid of undesired side effects associated with current antiangiogenic therapies (4) (5) (6) (7) . However, mechanisms of EPC-mediated tumor angiogenesis need further investigation.
MicroRNAs (miRNA/miR) are small noncoding RNAs (18-23bp in size) generated by the consecutive activity of two RNAseIII enzymes, DROSHA and DICER (8) . They regulate gene activity by sequence specific binding to messenger RNA (mRNA), triggering either translational repression or RNA degradation. It has been predicted that mammalian miRNAs regulate ~30% of all protein-coding genes (9) . MiRNAs have emerged as key regulators of several cellular processes, including angiogenesis (10) . A major indicator that miRNAs may contribute to angiogenesis came from the observation that suppression of DICER and DROSHA in vitro resulted in impaired angiogenesis (11) (12) (13) . It has also been shown that tissue specific inactivation of DICER, leads to impaired vascular development in the embryo (14) . However, miRNAs have not been directly implicated in EPC-mediated tumor angiogenesis in vivo.
Previously, we have demonstrated that the proximal promoter of the Inhibitor of DNA Binding 1 (Id1), in a retroviral context, can be used to genetically modify and deliver transgenes to EPCs Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 25, 2012; DOI:10.1158/0008-5472.CAN-12-0271 MicroRNA Regulation of Bone Marrow Mediated Tumor Angiogenesis. 5 in vivo (4) . We had shown that Id1 marked EPCs could be tracked from the BM compartment to the tumor bed, where they were eventually incorporated into the tumor vasculature. Using a similar strategy, we delivered Cre-recombinase to specifically excise floxed Dicer, the key miRNA processing enzyme in EPCs, which resulted in global miRNA loss and impaired EPCmediated tumor angiogenesis. To identify candidate miRNAs, we performed a genome-wide small RNA sequencing of tumor EPCs, revealing a miRNA profile that was more similar to vasculature from normal tissues and tumors, than either BM-derived myeloid and/or lineage depleted (Lin   -) cells. Notably, we also identified several miRNAs, in particular miR-10b and miR-196b (15) (16) (17) , which were up-regulated in tumor EPCs and tumor vasculature, compared with EPCs from wildtype animals and normal vasculature respectively. We also showed that miR-10b and miR-196b are regulated by tumor-conditioned media and vascular endothelial growth factor (VEGF) in endothelial cells; and that suppression of both miRNAs led to significant endothelial cell (EC) defects in vitro, as well as EPC-mediated impaired tumor growth in vivo. Taken together, these results underscore the importance of miRNAs in EPC-mediated tumor angiogenesis, and provide novel targets for future anti-angiogenic strategies.
Materials and Methods
Mice. The method for obtaining transgenic mice with the floxed DICER allele (18) and Crerecombinase, as well as the Id1 reporter mice (19) is outlined in the Supplementary Methods. MicroRNA Regulation of Bone Marrow Mediated Tumor Angiogenesis. 7 BulletKit™ media (Lonza, Valais, Switzerland), supplemented with VEGF and fibroblast growth factor (FGF). Murine endothelial cells (mHEVc) were provided by J. Cook-Mills (University of Cincinnati, Cincinnati, OH) (23) , and maintained in DMEM with 10% FCS. Cell authentication was conducted at ATCC by short tandem repeat profiling, cell morphology monitoring, karyotyping, and the ATCC cytochrome c oxidase. All cultures obtained were resuscitated from stocks frozen at low passage within 6 months of receipt.
BMT and tumor growth studies. BMT was conducted using previously published protocols Generation of Cre-recombinase lentiviral constructs. To deliver Cre-ERT2, under the control of the Id1 proximal promoter (Id1pr/p), Cre-ERT2 was inserted into a NotI site upstream of GFP in the lentiviral (LV) pWPT-Id1pr/p-GFP construct, as previously described (4 Locked nucleic acid (LNA) in situ hybridization (ISH) analysis of tissues. Cell specific small RNAs were detected by fluorescence microscopy using modification of previously published methods (26, 27) . After O.C.T removal, the slides were subjected to another round of fixation in 4% PFA (5-10min). The tissues were blocked (50×Denhardt's, 10mg/ml Yeast tRNA, Small RNA analysis of FACS isolated mouse cells. Total RNA was obtained (Trizol™, Invitrogen), and salts were removed using the Amicon-Ultra 0.5ml 3K columns (Millipore, Bedford, MA). RNA quality was assessed using the Nanodrop1000™ (ThermoScientific, Waltham, MA), prior to analysis. Library preparation and sequencing was conducted by R. King MicroRNA Regulation of Bone Marrow Mediated Tumor Angiogenesis.
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(GeneWorks, Adelaide, Australia), using the Illumina alternative v1.5 protocol for small RNA sequencing on the Illumina Genome Analyzer™ (Illumina, San Diego, CA). Two 'Spike-in' 5'-P and 3'-OH RNA oligonucleotides at 1pmol/10ȝg were used as internal normalisation controls:
Bioinformatic analysis was conducted on a high performance computing station (University of Queensland) that houses a local mirror of the UCSC Genome Browser20 (9), the Galaxy toolset (30) and a suite of publicly available and in-house programs. Library adaptors were removed using the FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Sequences were mapped using Bowtie (31) and were required to map uniquely to the genome without mismatches. MicroRNA expression was computed using an in-house Galaxy pipeline that takes all small RNA sequences that map to miRBase Release 16 pre-miRNA and mature miRNA annotations (32) . Relative expression differences were calculated for each feature using the spike control normalized values (see above). Those sequences that showed less than 300 normalized reads were excluded from further analysis.
To validate the representation of miRNAs identified in each library, real time quantitative reverse transcriptase PCR (Q-PCR) was conducted using miScript™ SYBR Green kit (Qiagen, Hilden, Germany). Amplification products were detected using the iCycler iQ™ (Bio-Rad, Hercules, CA). Relative fold differences in expression were determined using comparative analysis of mean control and test cycle threshold (¨¨CT) at linearity; with respect to one of two internal reference small RNAs: U5a or U6 (Qiagen) (¨CT) (33) .
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fig. S1B ). Impaired growth of these tumors was associated with >2-fold reduction in vessel density ( Supplementary Fig. S1C ).
Further analysis showed that administration of 4-OHT ablated DICER protein in VE-Cadherin + cells in the BM (Fig. 1A) . These results suggested that BM DICER ablation-mediated suppression of tumor growth and angiogenesis may be due to global miRNA loss.
After having observed a tumor phenotype following global DICER ablation in the BM, we used a more focused approach to determine the contribution of miRNAs in EPC-mediated tumor angiogenesis. To accomplish this we exploited our previously established selectivity of the Id1 proximal promoter (Id1pr/p) for EPCs (4) . We used the Id1pr/p to express Cre-ERT2 in lineage negative (Lin S3A ). After 8-weeks of BM engraftment, flow cytometry analysis of BM from these reconstituted mice showed that as expected ~5% of the BM cells express GFP, and that the GFP/CRE ERT2 expression was confined to c-kit + BM cells ( Supplementary Fig. S3B ). Analysis of LLC tumors in BMT animals treated with 4-OHT (Fig. 1C, D) . Importantly, CD11b + myeloid progenitors remained unchanged which is consistent with exquisite specificity of Id1pr/p for EPCs ( BMT animals ( Supplementary Fig. S3D ). Taken together, these findings suggest that functional DICER is required for BM-mediated tumor angiogenesis and that EPC-mediated tumor angiogenesis may be dependent on miRNAs generated by Dicer. Fig. S7A , B and Supplementary   Table S5C ).
ISH analysis of LLC, 4T1 and MDA-MB-231 tumors showed preferential expression of miR10b ( Fig. 3C and Supplementary Fig. S8A, B) , miR-196b and miR-132 (data not shown) in tumor vasculature, compared with vasculature from normal tissues ( Supplementary Fig. S8C, D) .
Cytoplasmic expression of miR-10b in tumor endothelium was confirmed by counterstaining with F-actin stain, Phalloidin ( Supplementary Fig. S9A ). While, in contrast miR-451 was downregulated in tumor vasculature and was expressed at a relatively high level in normal, non-tumor vasculature ( Supplementary Fig. S9B ).
To obtain insights into whether the candidate miRNAs, identified above, were up-regulated in the tumor vasculature in response to paracrine activity of the tumor cells, we treated murine Table S6B HOXD10 inhibits EC migration and angiogenesis (36, 37) . In this study we found that HoxD10 is up-regulated in EPCs impaired for miRNA biogenesis ( Supplementary Fig. S6) ; therefore, to determine whether miRNA regulation of Hox signaling plays a role in angiogenesis, we used antimiRs to inhibit either miR-10b or miR-196b and examined the effect on HOXD10 levels and EC function in human and murine ECs in vitro (37) . We used Cy3-conjugated anti-miRs to confirm efficient transfection of murine and human ECs ( Supplementary Fig. 11A, B) . Notably, Furthermore, suppression of miR-10b led to an increase in HOXD10, which was further confirmed by assessing its downstream target miR-7, which was up-regulated in human and mouse ECs (Fig. 5C, Supplementary Fig. S11E and Supplementary Methods) (38) . Notably, suppression of miR-196b also led to increased HOXD10, a finding that has not been previously reported; while levels of HOXA9 (39) remained unchanged (Fig. 5C ).
Administration of anti-miR-10b and anti-miR-196b results in EPC-mediated impaired tumor growth in vivo.
After having established that suppression of miR-10b and miR-196b leads to EC dysfunction, we next determined the effects of miR-10b and miR-196b suppression on angiogenesis-mediated tumor growth in vivo. We administered anti-miRs using RGD incorporated 'stealth liposomes' (34, 40) intravenously to target the tumor vasculature in mice bearing 4T1
tumors. The RGD-peptide, which recognizes intergin Į v ȕ 3 , expressed by tumour vasculature, was Supplementary Fig. S12A ). Notably, anti-miR-10b treated mice showed significantly reduced tumor volume and weight (Fig. 5D) . Two days after last treatment, significant FITC signal was detected in mononuclear cells from the BM (~5% of BMMNCs), peripheral blood (~0.08% of PBMNCs) ( Supplementary Fig. S12B ), and tumor vasculature ( Supplementary Fig. S12C ). This was associated with a significant reduction in the number of CEPs, but no change in myeloid cells in either anti-miR-10b, or anti-miR-196b treated mice was found ( Fig. 5E and Supplementary Fig. S12D ). Notably, tumors from anti-miR-10b treated mice showed a significantly reduced number of tumor ECs; as well as phenotypic changes in tumor vasculature (Fig. 5F ). Taken as a whole these data suggests that targeting miR-10b leads to significant EPC defects as well as a reduction in tumor growth.
Discussion
While the contribution of miRNAs to tumor angiogenesis has been reported (7, 13, 34) , the challenge of delivering transgenes to specific cell types in the BM-compartment of tumor-stroma, has precluded study of the biological function of EPC miRNAs and has impaired attempts to obtain a deeper understanding of their clinical significance. Furthermore, while EPC-associated miRNAs have been reported through in vitro studies (eg. miR-34a) (41), there has, as yet, been no direct link made between their expression by EPCs, and their significance to tumor vascular biology in vivo.
It is known that DICER-regulated miRNA biogenesis, is a key factor in normal cell function, embryological development, and stem cell biology (17) . In this study, we have used Dicer 19 mice, and exploited the selectivity of the Id1 proximal promoter-LV reporter (4) to mark EPCs to show for the first time that DICER is required for EPC-mediated tumor angiogenesis (Fig. 1) . This result concurs with a related finding, that DICER is required for vascular integrity during embryogenesis (14) .
To identify which miRNAs may be required for EPC-mediated tumor angiogenesis, we conducted small RNA deep sequencing analysis of EPCs, BM-derived myeloid cells and undifferentiated c-kit + cells (Fig. 2A, B) . These experiments revealed for the first time, an EPCintrinsic miRNA signature, which phenotypically distinguishes tumor EPCs from myeloid cells and Lin -BM derived cells. Of more than 100 miRNAs that were identified as differentially regulated in tumor-EPCs, several have been linked previously to EC function, including miR-221, which is believed to mediate release of EPCs from the BM by regulating c-kit (7, 13, 14) . Other miRNAs, such as miR-152, have not yet been linked to vascular biology, but have been shown to have functions such as regulation of DNA methylation (42) . MiR-10b and miR-196b, were also up-regulated in EPCs from the blood, BM and the tumor-stroma in syngeneic and human xenograft tumor mouse models (Fig. 2D, E) . Both of these miRNAs have previously been implicated in development and cancer biology (15) (16) (17) 36) . Notably, miR-126-3p and 5p, which inhibit proliferation (43), were significantly down-regulated in EPCs, which are known to expand and mobilize into the peripheral blood in response to tumor cytokines (2).
To identify how closely the EPC miRNA signature resembles that of tumor vasculature, a second round of deep sequencing and Q-PCR analysis, was conducted on mature endothelial cells, isolated from tumor vasculature (Fig. 3) . In agreement with our findings in EPCs, both miR-10b
and miR-196b were significantly up-regulated (8-100 fold) in tumor vasculature; while miR-451, an important tumor suppressor in lung cancer (44, 45) , was significantly down-regulated in tumor 20 vasculature. Notably, both miR-10b and miR-196b were found to be positively regulated by tumorconditioned medium; and miR-10b, like miR-132 was regulated by VEGF, in murine endothelial cells in vitro. Human endothelial cells in culture also showed increased levels of miR-10b and miR-196b, in response to tumor-conditioned medium and miR-10b levels were increased in response to VEGF (Fig. 4) . These results are supported by recent observations, which show that:
(i) HoxD10 (co-expressed with miR-10b) is co-regulated with VEGF in cancer (46) 
